Phosphorylation of the Chaperone-Like HspB5 Rescues Trafficking and Function of F508del-CFTR.
Aminophenols
/ pharmacology
Aminopyridines
/ pharmacology
Animals
Benzodioxoles
/ pharmacology
Cell Line
Cell Membrane
/ metabolism
Crystallins
/ metabolism
Cystic Fibrosis
/ genetics
Cystic Fibrosis Transmembrane Conductance Regulator
/ genetics
Drug Combinations
HEK293 Cells
Heat-Shock Proteins
/ metabolism
Humans
Male
Mice
Molecular Chaperones
/ genetics
Mutation
/ genetics
Phenylalanine
/ genetics
Phosphorylation
/ drug effects
Proteasome Endopeptidase Complex
/ metabolism
Protein Transport
/ drug effects
Quinolones
/ pharmacology
CFTR
CRYAB
HspB5
alpha B-crystallin
cystic fibrosis
phosphorylation
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
08 Jul 2020
08 Jul 2020
Historique:
received:
18
06
2020
revised:
02
07
2020
accepted:
04
07
2020
entrez:
12
7
2020
pubmed:
12
7
2020
medline:
17
2
2021
Statut:
epublish
Résumé
Cystic Fibrosis is a lethal monogenic autosomal recessive disease linked to mutations in Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein. The most frequent mutation is the deletion of phenylalanine at position 508 of the protein. This F508del-CFTR mutation leads to misfolded protein that is detected by the quality control machinery within the endoplasmic reticulum and targeted for destruction by the proteasome. Modulating quality control proteins as molecular chaperones is a promising strategy for attenuating the degradation and stabilizing the mutant CFTR at the plasma membrane. Among the molecular chaperones, the small heat shock protein HspB1 and HspB4 were shown to promote degradation of F508del-CFTR. Here, we investigated the impact of HspB5 expression and phosphorylation on transport to the plasma membrane, function and stability of F508del-CFTR. We show that a phosphomimetic form of HspB5 increases the transport to the plasma membrane, function and stability of F508del-CFTR. These activities are further enhanced in presence of therapeutic drugs currently used for the treatment of cystic fibrosis (VX-770/Ivacaftor, VX-770+VX-809/Orkambi). Overall, this study highlights the beneficial effects of a phosphorylated form of HspB5 on F508del-CFTR rescue and its therapeutic potential in cystic fibrosis.
Identifiants
pubmed: 32650630
pii: ijms21144844
doi: 10.3390/ijms21144844
pmc: PMC7402320
pii:
doi:
Substances chimiques
Aminophenols
0
Aminopyridines
0
Benzodioxoles
0
CFTR protein, human
0
Crystallins
0
Drug Combinations
0
Heat-Shock Proteins
0
Molecular Chaperones
0
Quinolones
0
lumacaftor, ivacaftor drug combination
0
Cystic Fibrosis Transmembrane Conductance Regulator
126880-72-6
ivacaftor
1Y740ILL1Z
Phenylalanine
47E5O17Y3R
Proteasome Endopeptidase Complex
EC 3.4.25.1
lumacaftor
EGP8L81APK
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Association Vaincre la Mucoviscidose
ID : na
Organisme : Institut National de la Santé et de la Recherche Médicale
ID : na
Organisme : Etablissement public - Chancellerie des universités de Paris
ID : na
Organisme : Association Mucoviscidose ABCF 2
ID : na
Organisme : Cystic Fibrosis Canada
ID : na
Organisme : IMRB fellowship for 'Translational Research'
ID : na
Références
Am J Respir Cell Mol Biol. 1993 May;8(5):522-9
pubmed: 7683197
Proc Natl Acad Sci U S A. 1993 Oct 15;90(20):9480-4
pubmed: 7692448
Nat Cell Biol. 2001 Jan;3(1):100-5
pubmed: 11146634
J Biol Chem. 2007 Nov 23;282(47):34276-87
pubmed: 17897943
Curr Pharm Biotechnol. 2010 Feb;11(2):146-57
pubmed: 20166966
Neurochem Int. 2018 May;115:69-79
pubmed: 29425965
Onco Targets Ther. 2019 May 30;12:4129-4139
pubmed: 31239701
Mucosal Immunol. 2019 Nov;12(6):1291-1303
pubmed: 31481750
Front Pharmacol. 2018 Sep 27;9:1100
pubmed: 30319426
J Cyst Fibros. 2019 Jan;18(1):35-43
pubmed: 29685812
Science. 1992 May 8;256(5058):774-9
pubmed: 1375392
Methods Mol Biol. 2011;742:335-53
pubmed: 21547742
Hum Mol Genet. 2010 Dec 1;19(23):4677-93
pubmed: 20843828
J Histochem Cytochem. 1990 Jan;38(1):31-9
pubmed: 2294148
Biochem J. 2002 Sep 15;366(Pt 3):797-806
pubmed: 12069690
Biochem Biophys Res Commun. 1989 Jan 16;158(1):319-25
pubmed: 2912453
Cancers (Basel). 2014 Feb 07;6(1):333-65
pubmed: 24514166
Mol Biol Cell. 2019 Jan 1;30(1):4-16
pubmed: 30403549
J Cyst Fibros. 2004 Aug;3 Suppl 2:191-6
pubmed: 15463957
Am J Physiol Cell Physiol. 2001 Nov;281(5):C1734-42
pubmed: 11600438
Am J Physiol Cell Physiol. 2007 Feb;292(2):C814-23
pubmed: 16987991
Br J Pharmacol. 2016 Jun;173(11):1728-41
pubmed: 26894321
Nat Commun. 2017 Aug 30;8(1):398
pubmed: 28855508
Oncotarget. 2017 Aug 19;8(43):74767-74780
pubmed: 29088822
Mol Biol Cell. 2007 Mar;18(3):806-14
pubmed: 17182856
Structure. 2004 May;12(5):871-9
pubmed: 15130479
FEBS Lett. 2007 Jul 31;581(19):3665-74
pubmed: 17467701
Mol Biol Cell. 2013 Jan;24(2):74-84
pubmed: 23155000
Pediatr Pulmonol. 2018 Nov;53(S3):S30-S50
pubmed: 29999593
J Biol Chem. 2002 Mar 29;277(13):11401-9
pubmed: 11799116
PLoS One. 2015 Nov 23;10(11):e0143366
pubmed: 26599332
J Biol Chem. 1999 Jul 2;274(27):18947-56
pubmed: 10383393
FEBS Lett. 1999 Jun 11;452(3):371-4
pubmed: 10386624
Biochem Biophys Res Commun. 2016 Oct 14;479(2):325-330
pubmed: 27641668
J Infect Dis. 2017 Dec 5;216(10):1308-1317
pubmed: 28968805
Chembiochem. 2016 Mar 15;17(6):493-505
pubmed: 26864378
J Biol Chem. 2015 Oct 16;290(42):25636-45
pubmed: 26336106
Mol Cell Proteomics. 2015 Jun;14(6):1569-83
pubmed: 25825526
EMBO J. 1995 Sep 15;14(18):4403-11
pubmed: 7556083
Cells. 2019 Apr 14;8(4):
pubmed: 31014000
Methods Mol Biol. 2011;741:13-21
pubmed: 21594775
Biomaterials. 2013 Jan;34(3):831-40
pubmed: 23117214
J Cell Sci. 2013 Sep 15;126(Pt 18):4160-72
pubmed: 23843626
Cell Physiol Biochem. 2008;22(1-4):57-68
pubmed: 18769032
Biochim Biophys Acta. 2015 Apr;1854(4):291-319
pubmed: 25556000
J Cell Sci. 2011 Oct 15;124(Pt 20):3381-92
pubmed: 22010196
Sci Rep. 2017 Aug 7;7(1):7375
pubmed: 28785019
Biochem J. 2008 Jul 1;413(1):135-42
pubmed: 18366345
Annu Rev Biochem. 2008;77:701-26
pubmed: 18304008
Nat Rev Mol Cell Biol. 2003 Mar;4(3):181-91
pubmed: 12612637